The Analysis Of National Drug Policy And The Application Of Pharmacoeconomics Evaluation In Chinese Drug Policy

National Drug Policy is an important part of national health policy. The target of national health policy is to make sure that everyone can enjoy the primary health care. From this point of view, nation drug policy has made its own strategic target, which is to meet the most people's need of essential drug, to make sure the drug is safety, efficacy and good quality, push forwards the rational use of drug. The main targets, key contexts and the relationship between them were analyzed in the thesis.In order to strengthen the management of basic medical drug, our country had made National Essential Drugs List and National Essential Medicare and Industrial Injury Insurance Formulary. Both of the two lists were effective in controlling the amount of drugs consumed, guaranteeing employees'access to essential drugs, ensuring drug quality, strengthening utilization review and containing rational escalation of drug expenditure.However, in the past few years, because of the phenomena of big prescription, backhander of drugs became more and more popular, drugs expenditure covered major part of medication charge, so medication problem has been a social-focused problem. Controlling the rising of drug costs has become a problem which needed to be solved. The study of pharmacoeconomics(PE) provides a new approach to solute the problem. Pharmacoeconomics is a newly developed discipline. It has been paid much attention by Chinese government and many sectors, such as health, labor and social security, drug administration, pricing departments and drug enterprises. PE evaluation method was applied to clinical trails. The efficacy, effectiveness, safety and value of drug usage were seriously concerned simultaneously.Theoretical analysis combined with the positive study was used in this article. In the thesis, the practices of pharmacoeconomics home and abroad were compared; the feasibility and future of PE evaluation in drug pricing, reimbursement, co-payment, hospital drug list and rational prescript in Chinese national drug policy were discussed.Chronic hepatitis B virus (HBV) infection is one of the most serious health problems in China. The disease burden due to HBV infection has been a great concern across the country. Statistics suggested that HBV infection accounted for major loss of health expenditures in China. Thymosin and lamivudine combination therapy on chronic hepatitis B(CHB) is very popular. The thymosin and lamivudine combination and thymosinα1 and lamivudine combination therapy on patients with chronic hepatitis B were compared. The economic effects of thymosin and lamivudine combination therapy on patients with CHB were accessed. This research can provide reference to clinical rational drugs use, adjust CHB drug policy, and release the social economics burden of CHB patients.